Announcing a new treatment for melanoma, along with two infographics (on Immuno-oncologY and Melanoma), and new animated videos on cancer and immuno-oncology!
Today, it was announced that KEYTRUDA® (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. KEYTRUDA is now the first and only anti-PD1 agent approved for first-line treatment regardless of BRAF mutation status.
A press release announcing this news was released earlier today and can be read here. The multi-media press release was issued with two infographics (on Immuno-oncology and Melanoma), and new animated videos on cancer and immuno-oncology.
We are also pleased to share to new amazing Patient Voice videos. We are continuously inspired by Save Your Skin Foundation patients, Mike and Pierre, who generously shared their stories for these videos.
Meet Mike: https://www.youtube.com/watch?v=rzCpNI7Huc8
Meet Pierre: https://www.youtube.com/watch?v=CiRdRboekYg
We are sharing all of this with you during an important time of year for skin cancer. Today marks the last day of Melanoma Awareness Month and it is the eve of International Cancer Immunotherapy Month (June). Save Your Skin Foundation will also be working to create further awareness of Sun Awareness Week (June 6-12) and National Cancer Survivor Day, which takes place on Sunday, June 5th.